Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 NSCLC 1 Liver Neoplasms 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Biphenotypic, Acute 1 Kidney Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Paclitaxel 134 Carboplatin 129 Bevacizumab 86 Gemcitabine 45 pembrolizumab 37 olaparib 33 Cisplatin 30 liposomal doxorubicin 29 Docetaxel 29 Cyclophosphamide 29 Topotecan 28 niraparib 27 Taxes 20 Etoposide 18 Filgrastim 16 Doxorubicin 16 Immunoglobulin G 15 Disulfides 15 apatinib 12 Letrozole 12 Albumin-Bound Paclitaxel 12 Drug Therapy 11 fluzoparib 10 fludarabine 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 Biopsy 10 durvalumab 9 Nivolumab 9 pazopanib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × Tyrosine Kinase Inhibitors × Clear all

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡